CA2378778C - Il-16 antagonists - Google Patents

Il-16 antagonists Download PDF

Info

Publication number
CA2378778C
CA2378778C CA2378778A CA2378778A CA2378778C CA 2378778 C CA2378778 C CA 2378778C CA 2378778 A CA2378778 A CA 2378778A CA 2378778 A CA2378778 A CA 2378778A CA 2378778 C CA2378778 C CA 2378778C
Authority
CA
Canada
Prior art keywords
seq
peptide
antagonist peptide
antagonist
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2378778A
Other languages
English (en)
French (fr)
Other versions
CA2378778A1 (en
Inventor
David M. Center
William W. Cruikshank
Hardy Kornfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of CA2378778A1 publication Critical patent/CA2378778A1/en
Application granted granted Critical
Publication of CA2378778C publication Critical patent/CA2378778C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
CA2378778A 1999-08-05 2000-08-04 Il-16 antagonists Expired - Fee Related CA2378778C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/368,630 US6699466B1 (en) 1999-08-05 1999-08-05 IL-16 antagonist peptides and DNA encoding the peptides
US09/368,630 1999-08-05
PCT/US2000/021317 WO2001010893A2 (en) 1999-08-05 2000-08-04 Il-16 antagonists

Publications (2)

Publication Number Publication Date
CA2378778A1 CA2378778A1 (en) 2001-02-15
CA2378778C true CA2378778C (en) 2011-04-19

Family

ID=23452058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2378778A Expired - Fee Related CA2378778C (en) 1999-08-05 2000-08-04 Il-16 antagonists

Country Status (6)

Country Link
US (6) US6699466B1 (https=)
EP (1) EP1212363A2 (https=)
JP (1) JP2003507011A (https=)
CA (1) CA2378778C (https=)
MX (1) MXPA02001268A (https=)
WO (1) WO2001010893A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
AU2003213963A1 (en) * 2002-04-08 2003-10-27 The John P. Robarts Research Institute Method of treating or preventing autoimmune disease
FR2869528B1 (fr) * 2004-04-28 2007-02-02 Ldr Medical Prothese de disque intervertebral
WO2009129374A2 (en) * 2008-04-18 2009-10-22 Trustees Of Boston University Methods and compositions for preventing adhesion
DK2318020T3 (en) 2008-06-30 2015-11-30 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
SG10201913509YA (en) * 2016-04-28 2020-02-27 Nat Univ Singapore Therapeutic sall4 peptide
CN117860892B (zh) * 2023-12-26 2024-08-06 武汉大学中南医院 Il-16阳性神经元在调节恐惧消退记忆中的作用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
ES2320090T3 (es) * 1993-05-21 2009-05-19 Trustees Of Boston University Factor quimiotactico de linfocitos y usos del mismo.
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2216755A1 (en) * 1995-03-31 1996-10-03 Brian Lee Buckwalter Peptides with growth promotion properties
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
DE19649233A1 (de) * 1996-11-28 1998-06-04 Boehringer Mannheim Gmbh Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
JP2001520748A (ja) * 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
DE69837542T2 (de) * 1997-04-15 2008-01-31 Merck & Co, Inc. Ldl-rezeptor
AU2424399A (en) 1998-01-24 1999-08-09 Bundesrepublik Deutschland Mutants of il-16, processes for their production, and their use
EP1066047A4 (en) 1998-03-25 2004-10-13 Mayo Foundation For Medicaledu METHOD AND SUBSTANCES FOR TREATING FLAMMABLE DISEASES
US6699466B1 (en) * 1999-08-05 2004-03-02 Research Corporation Technologies, Inc. IL-16 antagonist peptides and DNA encoding the peptides

Also Published As

Publication number Publication date
US20030153504A1 (en) 2003-08-14
CA2378778A1 (en) 2001-02-15
US20100008936A1 (en) 2010-01-14
US20070031375A1 (en) 2007-02-08
WO2001010893A3 (en) 2001-08-16
US7608691B2 (en) 2009-10-27
JP2003507011A (ja) 2003-02-25
EP1212363A2 (en) 2002-06-12
WO2001010893A2 (en) 2001-02-15
US7914778B2 (en) 2011-03-29
US20110207679A1 (en) 2011-08-25
MXPA02001268A (es) 2003-09-10
US20120213790A1 (en) 2012-08-23
US7208149B2 (en) 2007-04-24
US6699466B1 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
US20120213790A1 (en) Methods of treatment using il-16 antagonist peptides
US5672347A (en) Tumor necrosis factor antagonists and their use
ES2213148T3 (es) Anticuerpo monoclonal dirigido contra el vih.
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
CA2293735A1 (en) Lag-3 splice variants
JP2007169287A (ja) 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
US6172042B1 (en) Synthetic peptides that inhibit IL-6 activity
EP0989858B1 (en) Cd28/ctla-4 inhibiting peptidomimetics and pharmaceutical compositions thereof
US6664374B1 (en) Polypeptides comprising IL-6 ligand-binding receptor domains
WO1998000535A2 (en) Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
EP1161455A1 (en) A novel chimeric protein for prevention and treatment of hiv infection
JP4813720B2 (ja) ヒト循環ウイルス阻害ペプチド（ｖｉｒｉｐ）及びその使用
US6011014A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US6709649B1 (en) RANTES derived peptides with anti-HIV activity
WO1998033067A1 (en) Transcription factors that repress hiv transcription and methods based thereon
AU731975B2 (en) GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection
WO1998015569A9 (en) Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
US7232801B2 (en) IL-16 antagonists
EP0960886A1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US7510715B2 (en) Protozoan derived compositions and methods of use thereof
WO1997025350A1 (en) Use of chemokines for the treatment and prevention of hiv infection
Agentsa Implications for the Design of Small-Peptide
Tretiakova et al. A rational design approach for developing immunomodulators based on CD4 and CD8

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160804